Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева. 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310. 3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1.
Список исп. литературыСкрыть список 1. Беккер Р. А., Быков Ю. В., Морозов П. В. Выдающиеся психиатры ХХ века. — М.: ИД «Городец»; 2019. 2. Беккер Р. А., Быков Ю. В. Пролонгированные антипсихотики компании «Янссен» в историческом разрезе: прошлое, настоящее, будущее //Психиатрия и психофармакотерапия. — 2017. — Т. 19. — № 6. — С. 18–27. 3. Быков Ю. В., Беккер Р. А. Тревикта — первый сверхпролонгированный антипсихотик III поколения: эффективность, безопасность и практические аспекты применения //Психиатрия и психофармакотерапия. — 2019. — Т. 21. — № 6. — С. 11–23. 4. Гурович И. Я., Шмуклер А. Б. Психосоциальная и когнитивная терапия и реабилитация психически больных //Под ред. Гурович И. Я., Шмуклер А. Б. — М.: ИД Медпрактика-М. — 2015. 5. Казаковцев Б. А., Демчева Н. К. с соавт. Реформирование психиатрических служб и показатели заболеваемости психическими расстройствами в Российской Федерации в 2014–2016 гг. //Психическое здоровье. — 2017. — Т. 15. — № 10. — С. 15–26. 6. Alphs L, Bossie C, Mao L et al. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Interv Psychiatry. 2018;12(1):55-65. 7. Alphs L, Bossie CA, Sliwa JK et al. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatr Dis Treat. 2013;9:341-50. 8. Anderson JP, Icten Z, Alas V et al. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17(1):346. 9. Arango C, Baeza I, Bernardo M et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. [Article in English, Spanish]. Rev Psiquiatr Salud Ment. 2019;12(2):92-105. 10. Bai Z, Wang G, Cai S, et al. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis. Schizophr Res. 2017;185:73-79. 11. Cheung S, Hamuro Y, Mahlich J et al. Drug utilization of Japanese patients diagnosed with schizophrenia: an administrative database analysis. Clin Drug Investig. 2017;37(6):559-569. 12. Choon JWY, Wu DBC, Chong HY et al. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong. J Med Econ. 2019;22(3):273-279. 13. Fu DJ, Bossie CA, Sliwa JK et al. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Int Clin Psychopharmacol. 2014;29(1):45-55. 14. Fu DJ, Turkoz I, Walling D et al. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophr Res. 2018;192:185-193. 15. Fujii Y, Iwata N, Takahashi K. Large-scale about psychiatrists’ use, knowledge and attitudes to depot antipsychotics: a comparison between Japanese and German psychiatrist. Jpn J Clin Psychpharmacol. 2012;15:797-810. 16. Gaviria AM, Franco J, Rico G et al. Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Spanish Province of Tarragona Catchment Area. Prim Care Companion CNS Disord. 2017;19(2). 17. Gaviria AM, Franco JG, Aguado V et al. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona. PLoS One. 2015;10(10): e0139403. 18. Hegarty JD, Baldessarini RJ, Tohen M et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409-1416. 19. Hsu HF, Kao CC, Lu T et al. Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services. J Clin Med. 2019;8(6). pii: E823. 20. Jonsdottir A, Waghorn G. Psychiatric disorders and labour force activity. Ment Health Rev Jr 2015;20:13. 21. Kane JM, Correll CU. Schizophrenia: Pharmacological Treatment. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 22. Kim E, Correll CU, Mao L et al. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS Spectr. 2016;21(6):466-477. 23. Kishimoto T, Sanghani S, Russ MJ et al. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting. Int Clin Psychopharmacol. 2017;32(3):161-168. 24. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279-293. 25. Koshikawa Y, Takekita Y, Kato M et al. The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. Neuropsychobiology. 2016;73(1):35-42. 26. Kozma C, Dirani R, Canuso C, Mao L. Change in employment status over 52 weeks in patients with schizophrenia: an observational study. Curr Med Res Opin. 2011;27:327-333. 27. Li H, Rui Q, Ning X et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002-8. 28. Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.Clinicoecon Outcomes Res. 2015;7:267-72. 29. Mahlich J, Olbrich K, Wilk A et al. Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study. Clin Drug Investig. 2020 Mar 9. 30. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10:23-41. 31. Miura G, Misawa F, Kawade Y et al. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study. J Clin Psychopharmacol. 2019;39(5):441-445. 32. Montalvo I, Ortega L, López X et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol. 2013;28: 46-49. 33. Munday J, Greene M, Chang E et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Curr Med Res Opin. 2019;35(7):1231-1239. 34. Nasrallah HA, Chen AT. Multiple neurotoxic effects of haloperidol resulting in neuronal death. Ann Clin Psychiatry, 2017;29(3):195-202. 35. Olayinka O, Oyelakin A, Cherukupally K et al. Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital. Psychiatry J. 2019;2019:8629030. 36. Quintero J, Oyagüez I, González B et al. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. Clin Drug Investig. 2016;36(6):479-90. 37. Si T, Li N, Lu H et al. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. J Psychopharmacol. 2018;32(6):691-701. 38. Si T, Zhuo J, Feng Y et al. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1685-1694. 39. Si T, Zhuo J, Turkoz I et al, 2017. Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety. Expert Opin Pharmacother. 2017;18(17):1799-1809. 40. Song X, El Khoury AC, Brouillette M et al. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019;22(11):1105-1112. 41. Souetre E. Economic evaluation in schizophrenia. Neuropsychobiology. 1997;35:67-69. 42. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4th Ed. 2013. ISBN 978-1-107-68646-5. 43. Suda A, Hattori S, Kishida I et al. Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients. Neuropsychiatr Dis Treat. 2018;14:2361-2366. 44. Sugawara N, Kudo S, Ishioka M et al. Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan. Neuropsychiatr Dis Treat. 2019;15:205-211. 45. Tajima-Pozo K, Reinoso Barragán S et al. [Treatment adherence and effectiveness of extended-release antipsychotics in a hospital setting]. [Article in Spanish]. Vertex. 2019;XXX(143):46-51. 46. Takekita Y, Koshikawa Y, Fabbri C et al. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry. 2016;16:172. 47. Tamminga CA. Schizophrenia: Introduction and Overview. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. — 2017. 48. Trauer T, Duckmanton RA, Chiu E. Estimation of costs of public psychiatric treatment. Psychiatr Serv. 1998;49:440-442. 49. Usuki M, Kamiura Y, Okubo R, Yamanouchi Y. National database study on the use of long-acting antipsychotic injections and hospital readmission proportions in patients with schizophrenia in Japan. Psychiatry Clin Neurosci. 2020;74(3):211-217. 50. Vázquez-Mourelle R, Parrondo CD, López-Pardo Pardo E, Carracedo-Martínez E. [Efficiency of a pharmaceutical care program for long-acting parenteral antipsychotics in the health area of Santiago de Compostela]. [Article in Spanish]. Gac Sanit. 2016;30(1):73-6. 51. Wei YY, Lin WF, Zhang TH et al. Effectiveness of traditional Chinese medicineas as an adjunct therapy for refractory schizophrenia: a systematic review and meta-analysis. Sci Rep. 2018;8(1):6230. 52. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: WHO Press; 2008. 53. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30:196-205. 54. Yoshimatsu K, Elser A, Thomas M et al. Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population. Community Ment Health J. 2019;55(6):979-982. 55. Zeidler J, Mahlich J, Greiner W, Heres S. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11(5):509-21. 56. Zhang L, Li J, Zhao Y et al. Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatr Dis Treat. 2016;12:113-31. 57. Zhou H, Wang S. Clinical efficacy of paliperidone in treatment of first episode schizophrenia. The Journal of Practical Medicine. 2012;28(23):3986-3988.